Navigation Links
Peregrine Pharmaceuticals Mourns Loss of Chairman Thomas A. Waltz
Date:12/11/2008

TUSTIN, Calif., Dec. 11 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that Thomas A. Waltz, M.D., chairman of its Board of Directors, unexpectedly passed away on Wednesday. Dr. Waltz had been a director of Peregrine since 2004 and was chairman since 2005. At the time of his death, Dr. Waltz served on Peregrine's Audit Committee, Compensation Committee and Nominating Committee.

"The sudden loss of our business colleague and friend Tom Waltz brings sadness to the entire Peregrine family," said Steven W. King, president and CEO of Peregrine. "Our deepest sympathies go out to Tom's family and to all who knew him well. Tom's distinguished career as a top neurosurgeon and healthcare executive was matched by his generosity and spirit. His medical and healthcare expertise was of significant value to Peregrine and his talents, wisdom and guidance will be missed."

Dr. Waltz was a neurosurgeon and a senior consultant in Neurosurgery at the Scripps Clinic in La Jolla, California. He formerly was chairman and CEO of the Scripps Clinic and president of the Scripps Clinic Medical Group. Dr. Waltz also served on the Board of Genoptix Inc. and Premera Blue Cross of Washington and Alaska. He received his undergraduate degree from the University of Cincinnati, his M.D. from Vanderbilt University and his neurosurgical training at Baylor College of Medicine. Dr. Waltz also had training in Neurology at The National Hospital for Neurological Diseases and in Neuropathology at Oxford University, both in the U.K.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

    Contacts:
    GendeLLindheim BioCom Partners
    Investors                                Media
    info@peregrineinc.com                    Barbara Lindheim
    (800) 987-8256                           (212) 918-4650


'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Peregrine Pharmaceuticals Enters Into a Loan Agreement for up to $10 Million
2. Peregrine Pharmaceuticals to Report Second Quarter FY 2009 Financial Results
3. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
4. Peregrine Pharmaceuticals to Present at BIO Investor Forum 2008
5. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
6. Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
7. Peregrine Pharmaceuticals Completes Patient Enrollment In First Stage of Bavituximab Phase II Lung Cancer Trial
8. Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009
9. Peregrine Pharmaceuticals to Report First Quarter FY 2009 Financial Results
10. Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
11. Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)...   Boston Biomedical , an industry leader ... target cancer stemness pathways, announced that its lead ... Designation from the U.S. Food and Drug Administration ... gastroesophageal junction (GEJ) cancer. Napabucasin is an orally ... stemness pathways by targeting STAT3, and is currently ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) is ... treatments and faster cures for prostate cancer. Members of the Class of 2016 ... countries. Read More About the Class of 2016 PCF ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published today ... a patient who developed lymphedema after being treated for breast cancer benefitted from an ... paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
Breaking Biology Technology:
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
(Date:5/3/2016)... 2016  Neurotechnology, a provider of high-precision biometric ... Biometric Identification System (ABIS) , a complete system ... ABIS can process multiple complex biometric transactions with ... fingerprint, face or iris biometrics. It leverages the ... MegaMatcher Accelerator , which have been used ...
(Date:4/26/2016)... BANGALORE, India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a ... ), and Onegini today announced a partnership to ... banking solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... banks to provide their customers enhanced security to ...
Breaking Biology News(10 mins):